Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).

被引：0

作者：

Santoro, A.

Voglova, J.

Gabrail, N.

Ciuleanu, T.

Liberati, M.

Hancock, B. W.

Stromatt, S.

Caballero, D.

机构：

[1] Ist Clin Humanitas, Rozzano, Italy

[2] Internal Clin, Dept Clin Haematol, Hradec Kralove, Czech Republic

[3] Gabrail Canc Ctr, Canton, OH USA

[4] Inst Oncol, Cluj Napoca, Romania

[5] Univ Perugia, I-06100 Perugia, Italy

[6] Weston Pk Hosp, Sheffield, S Yorkshire, England

[7] Cell Therapeut Inc, Seattle, WA USA

[8] Hosp Clin Salamanca, Serv Hematol, Salamanca, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：441S / 441S

页数：1